
- ONCOLOGY Vol 24 No 6
- Volume 24
- Issue 6
NCI-Sponsored Study Finds Increased Risk of False-Positives in CT Lung Cancer Screening
Results of a new study published in the Annals of Internal Medicine [Ann Intern Med 152:505-512, 2010] indicate that the risk for false-positive results of CT lung cancer screening tests is substantial. Led by Jennifer M. Croswell, MD, researchers from NCI sought to quantify the cumulative risk in a 1- or 2-year lung cancer screening exam, based on at least one false-positive finding.
Results of a new study published in the Annals of Internal Medicine [Ann Intern Med 152:505-512, 2010] indicate that the risk for false-positive results of CT lung cancer screening tests is substantial. Led by Jennifer M. Croswell, MD, researchers from NCI sought to quantify the cumulative risk in a 1- or 2-year lung cancer screening exam, based on at least one false-positive finding. In addition to determining the rates of false-positive findings, the investigators identified rates of unnecessary diagnostic procedures that are potentially brought on by these false-positive findings. The randomized controlled trial of low-dose CT vs chest radiography (ClinicalTrials.gov registration number: NCT00006382) found that the risks of false-positive results of lung cancer screening tests are substantial after only two annual examinations, particularly for low-dose CT. The authors recommended further study of resulting economic, psychosocial, and physical burdens of these methods.
Articles in this issue
about 16 years ago
Diagnosis and Management of Mycosis Fungoidesabout 16 years ago
Navigating the Treatment Choices for Mycosis Fungoidesabout 16 years ago
The Role of Bisphosphonates in the Adjuvant Setting for Breast Cancerabout 16 years ago
Comparative Effectiveness and Comparative Costsabout 16 years ago
Turmeric (Curcuma longa, Curcuma domestica)about 16 years ago
Quality-Adjusted Life-Years, Comparative Effectiveness in Cancer CareRelated Content



107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)




















































